Search clinical trials for: Pradaxa (dabigatran etexilate)

Total 299 results

Boehringer Ingelheim

Completed

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

Healthy Volunteers

China
University of Utah

Terminated

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation (DEPAF)

Atrial Fibrillation

United States
Nova Scotia Health Authority
Dalhousie University; Université de Montréal; Capital Health, Canada

Completed

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Blood Coagulation Disorders

Canada
Boehringer Ingelheim

Completed

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Healthy

Japan
Ross Leighton
Nova Scotia Health Authority

Withdrawn

A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days

Thromboembolism

Canada
Irina Ermolaeva

Recruiting

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD (RE-ELECT)

Chronic Kidney Diseases | Atrial Fibrillation | T2DM (Type 2 Diabetes Mellitus)

Russian Federation
Boehringer Ingelheim

Completed

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Atrial Fibrillation

Taiwan
Boehringer Ingelheim

Recruiting

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot (DaPaR)

Venous Thromboembolism

Spain, Germany, Netherlands, Czechia, Finland, Sweden
The University of Hong Kong

Recruiting

Dabigatran for Mitral Stenosis Atrial Fibrillation

Atrial Fibrillation | Mitral Stenosis

Hong Kong
Bayer

Completed

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Hot Flashes | Healthy Volunteers | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Boehringer Ingelheim

Completed

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Atrial Fibrillation

Korea, Republic of
Vanderbilt University Medical Center
Boehringer Ingelheim

Completed

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

Atrial Fibrillation | Atrial Flutter

United States
Intermountain Health Care, Inc.
Boehringer Ingelheim

Completed

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)

Dementia | Cognition Disorders | Cerebral Ischemic Events

United States
Medical University of South Carolina
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Interstitial Lung Disease | Scleroderma

United States
Research Institute for Complex Problems of Cardiovascular...

Unknown

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

Atrial Fibrillation | Mitral Valve Stenosis and Insufficiency

Russian Federation
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
Peking University Third Hospital

Recruiting

Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults

Health

China
Corcept Therapeutics

Completed

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Neoplasms | Cushing Syndrome

United States
Mayo Clinic

Terminated

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Acute Pancreatitis

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Completed

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults

Healthy

Belgium
Boehringer Ingelheim

Completed

Japanese Pradaxa PMS, Long Term

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects

Healthy
Johannes Gutenberg University Mainz
Boehringer Ingelheim; Atrial Fibrillation Network

Terminated

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF (RE-LATED_AF)

Atrial Fibrillation or Atrial Flutter | Thrombosis of Left Atrial Appendage

Germany
Wuhan Asia Heart Hospital

Completed

D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy (DIRECT)

Atrial Fibrillation | Strokes Thrombotic

China
Boehringer Ingelheim

Completed

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Atrial Fibrillation

United States, Canada
Boehringer Ingelheim

Completed

A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Venous Thrombosis | Arthroplasty, Replacement, Knee

Japan
National Cheng-Kung University Hospital
Tainan Municipal Hospital; E-DA Hospital; Ministry of Health and Welfare, Taiwan and other collaborators

Unknown

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation (DARING-AF)

Atrial Fibrillation

Taiwan
Hospital Ana Nery

Terminated

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively (DAWA)

Primary Disease

Brazil
Boehringer Ingelheim

Completed

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

Healthy
University of Alberta

Completed

Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke (DATAS)

Transient Ischemic Attack | Minor Ischemic Stroke

Canada
Vanderbilt University Medical Center
Boehringer Ingelheim

Active, not recruiting

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). (DEA-LAA)

Atrial Fibrillation | Left Atrial Appendage Thrombosis | Device Related Thrombus | Watchman LAA Closure Device

United States
The University of Hong Kong

Unknown

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism

Hong Kong
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

Renal Insufficiency
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Venous Thromboembolism (VTE)

Sweden
Boehringer Ingelheim

Terminated

Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN)

Heart Valve Diseases

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
Boehringer Ingelheim

Terminated

Follow on Study From RE-ALIGN

Thromboembolism | Heart Valve Prosthesis

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland
Boehringer Ingelheim

Completed

Medical Need of OAC Reversal

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Boehringer Ingelheim

Completed

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Healthy

Germany
Centre Hospitalier Universitaire de Saint Etienne
Groupe de Recherche sur la Thrombose

Completed

Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin (IMAGINE)

Healthy

France
Boehringer Ingelheim

Completed

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Healthy
Pfizer

Terminated

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Healthy

United States
University Hospital, Essen

Completed

Registration of Idarucizumab for Patients With IntraCranial Hemorrhage (RIC-ICH)

Intracranial Hemorrhage

Germany
Ural State Medical University
Boehringer Ingelheim

Unknown

Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study) (RE-SOUND)

Atrial Fibrillation

Russian Federation
Boehringer Ingelheim

Completed

Safety and Tolerability of Dabigatran Etexilate in Adolescents

Venous Thromboembolism

Canada

3

Subscribe